Published on 28 Feb 2024 on Exec Edge via Yahoo Finance
By Daniella Parra
Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management.
Start tracking your investments with Statfolio
U.S. stocks on Friday kicked off the month of March on a positive note, after largely negative...
Key Insights Vivani Medical's significant individual investors ownership suggests that the key de...
Vivani Medical secures $15 million in direct offering
Shares of Bumble Inc. BMBL fell sharply during Wednesday’s session following weak quarterly resu...
, opens new tab shares surged more than five-fold in early trading on Wednesday after the drug...
By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for ...
Vivani Medical, Inc. ( NASDAQ :VANI), a biopharmaceutical company, has announced positive...
Investors who take an interest in Vivani Medical, Inc. (NASDAQ:VANI) should definitely note that ...
On September 12, 2023, Director Gregg Williams made a significant investment in Vivani Medical In...